Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

tors presented positive results from Phase 2 clinical trials of Amigal at the American College of Medical Genetics (ACMG) meeting. The data showed that Amigal was generally safe and well-tolerated at all doses evaluated and no drug-related serious adverse events were reported. In addition, Amigal increased the level of the enzyme deficient in Fabry patients in 24 of 26 study subjects, and in a majority of study subjects the treatment resulted in a reduction of kidney GL-3 as measured in urine.

Amicus, along with its partner Shire, has initiated discussions with the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regarding its plans for Phase 3 clinical evaluation of Amigal. Amicus expects to complete these interactions and provide an update in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate the Phase 3 clinical trial in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients continue to be treated with Amigal in the voluntary Phase 2 extension study to monitor long term safety and efficacy. In addition, the Company will evaluate modified doses and dose regimens in these 23 patients. Data from this extension study are expected to be available by Q1 2009, prior to finalization of the Phase 3 protocol.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic being developed for the treatment of Gaucher disease. At the ACMG meeting in March, clinical investigators presented full data from a 4 week Phase 2 study in Gaucher patients who switched from enzyme replacement therapy (ERT) with imiglucerase to the pharmacological chaperone Plicera. Results showed that Plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. In the trial, GCase activity, as measured in white blood cells, was increased in 20 of the 26 pat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... commentary on clinical study data involving ADXS31-164 (AT-014) ... at the American Association for Cancer Research (AACR) ... novel Lm -LLO immunotherapy developed by Advaxis, ...
(Date:4/27/2015)... HEIDELBERG , Germany , April ... need in treatment of millions of cancer patients   ... a patent in Europe entitled ... Health,s discovery that EPHB4 is a novel receptor for Erythropoietin ... stimulates the production of red blood cells and is ...
(Date:4/27/2015)... 27, 2015 tru Shrimp™ Systems announced ... Texas A&M University for the exclusive worldwide rights to ... raceway systems. The license agreement for the patented technology, ... to countries such as China, Taiwan, France, Germany, Italy, ... “We have had inquires from all over the world ...
(Date:4/27/2015)... , April 27, 2015 Elsevier ... products and services, and Qatar University Research Office   have ... Awards. The awards ceremony, held last week at ... , was attended by more than 40 guests representing ... were presented by Professor Sheikha Abdulla Al-Misnad , President ...
Breaking Biology Technology:Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2tru Shrimp™ Systems Acquires Global Patent for Tidal Basin™ Shrimp Production 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 4Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 5
... Nov. 24 Boston Scientific,Corporation (NYSE: BSX ) ... which is being held December 2 - 3 in New ... will make a 30-minute presentation on,Tuesday, December 2, beginning at ... A live webcast of Mr. Tobin,s remarks will be ...
... CLAREMONT, Calif., Nov. 24 Keck Graduate Institute,s (KGI) Biotechnology ... educational event on Monday, Dec. 8, 2008. , ... (TCA), a network of individual investors who fund early-stage, technology ... of the public interested in becoming angel investors. The ...
... Omrix,s Biopharmaceutical Expertise Complements ETHICON,s Industry-Leading Surgery Portfolio ... N.J. and NEW YORK, Nov. 24 Johnson & ... Inc. (Nasdaq: OMRI ), a fully integrated ... products, today announced a definitive agreement whereby Omrix will ...
Cached Biology Technology:KGI Entrepreneur Program Hosts Angel Investing Educational Meeting 2Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 2Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 3Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 4Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 5
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... 13, 2015  higi, a leading cloud-based consumer engagement ... fully engage with their communities around health and wellness, ... and secure API.  ... accessible, affordable, and convenient vehicle to receive validated health ... The API will allow higi,s trusted partners, ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... The Scripps Research Institute (TSRI) have found an easier way to ... new method allows scientists to add a marker to certain cells, ... from a larger cell population. The technique, which is ... Chemie International Edition , makes use of the tight binding of ...
... (RQR), Palais des congrs de Montral, Montral, Qubec, Canada, 22-26 ... 2013 -- The Society for the Study of Reproduction ... the 46th SSR Annual Meeting to be held in Montral, ... Meetings page ( http://www.ssr.org/Meetings.shtml ) for details; information will be ...
... New Rochelle, NY, January 8, 2013The world,s leading zebrafish ... promote science education. Scientific papers, many authored by students ... curricula and educational tools, a collection of abstracts (including ... from the recent Zebrafish in Education Workshops ...
Cached Biology News:Chemists devise inexpensive, benchtop method for marking and selecting cells 2Chemists devise inexpensive, benchtop method for marking and selecting cells 3Surprising teaching tool in K-12 science education -- Zebrafish research 2
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human Serpin A8/AGT Affinity Purified Polyclonal Ab Keywords: Ang II, AngII, Hypertension, Salt Homeostasis, Pre-eclampsia...
Human CXCL14/BRAK Affinity Purified Polyclonal Ab...
Human/Mouse G9a/EHMT2 MAb (Clone A8620A) Keywords: Eu-HMTase2...
Biology Products: